Art. -Nr.: HY-13032

Copy Link Print Information

Molibresib

(Synonyms: I-BET762; GSK525762; GSK525762A)

23 Cited Publications

Kundenbewertung

Based on 23 publication(s) in Google Scholar

Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC₅₀ of 32.5-42.5 nM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.94%
CAS. Nr.: 1260907-17-2
Formel: C₂₂H₂₂ClN₅O₂
Molecular Weight:423.90

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Molibresib Chemical Structure

CAS. Nr.: 1260907-17-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (23)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Bioz

Biologische Aktivität

Beschreibung

Molibresib (I-BET762; GSK525762) is a BET bromodomain inhibitor with IC₅₀ of 32.5-42.5 nM.

IC₅₀ & Target

IC50: 32.5-42.5 nM (BET)^[1]

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
697	EC₅₀	1.17 μM Compound: 2; GSK525762A	Cytotoxicity against human 697 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay Cytotoxicity against human 697 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay	[PMID: 29170024]
HepG2	EC₅₀	700 nM Compound: 2, GSK525762A	Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay	[PMID: 21568322]
HepG2	EC₅₀	700 nM Compound: 3, I-BET762, GSK525762A	Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay Induction of human ApoA1 gene expression in stably transfected human HepG2 cells coexpressing luciferase reporter gene after 18 hrs by luminescence assay	[PMID: 22924434]
HL-60	IC₅₀	0.12 μM Compound: I-BET762	Cytotoxicity against human HL60 cells by MTS assay Cytotoxicity against human HL60 cells by MTS assay	[PMID: 29657099]
K562	IC₅₀	>2000 nM Compound: 2, I-BET-762	Cytotoxicity against human K562 cells harboring BCR-ABL fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay Cytotoxicity against human K562 cells harboring BCR-ABL fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay	[PMID: 26080064]
Kasumi 1	IC₅₀	0.21 μM Compound: 1; IBET762	Antiproliferative activity against human Kasumi-1 cells after 72 hrs by Celltiter-Glo assay Antiproliferative activity against human Kasumi-1 cells after 72 hrs by Celltiter-Glo assay	[PMID: 30905542]
LNCaP	IC₅₀	356.5 nM Compound: 2; I-BET762	Antiproliferative activity against human LNCAP cells Antiproliferative activity against human LNCAP cells	[PMID: 29758518]
LOUCY	EC₅₀	>5 μM Compound: 2; GSK525762A	Cytotoxicity against human Loucy cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay Cytotoxicity against human Loucy cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay	[PMID: 29170024]
MM1.S	IC₅₀	0.23 μM Compound: 2; I-BET762	Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay	[PMID: 28586718]
MM1.S	IC₅₀	349.2 nM Compound: 2; I-BET762	Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay Antiproliferative activity against human MM1S cells after 72 hrs by CCK8 assay	[PMID: 29525435]
MM1.S	IC₅₀	141 nM Compound: 1; I-BET762	Antiproliferative activity against human MM1S cells assessed as cell growth inhibition after 4 days by CCK8 assay Antiproliferative activity against human MM1S cells assessed as cell growth inhibition after 4 days by CCK8 assay	[PMID: 31461688]
MOLM-13	IC₅₀	241 nM Compound: 2, I-BET-762	Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay Cytotoxicity against human MOLM13 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay	[PMID: 26080064]
MOLM-13	IC₅₀	241 nM Compound: 4; I-BET762	Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay Growth inhibition of human MOLM13 cells after 4 days by WST-8 assay	[PMID: 28463487]
MV4-11	IC₅₀	102 nM Compound: I-BET762, GSK525762A	Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay Antiproliferative activity against human MV4-11 cells assessed as inhibition of cell growth incubated for 72 hrs by CellTiter-Glo assay	[PMID: 21964340]
MV4-11	IC₅₀	93 nM Compound: 2, I-BET-762	Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay Cytotoxicity against human MV4-11 cells harboring MLL1 fusion gene assessed as growth inhibition after 4 days by CellTiter-Glo luminescent assay	[PMID: 26080064]
MV4-11	IC₅₀	93 nM Compound: 4; I-BET762	Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay Growth inhibition of human MV4-11 cells after 4 days by WST-8 assay	[PMID: 28463487]
MV4-11	IC₅₀	0.8 μM Compound: 1; I-BET762	Cytotoxicity against human MV411 cells after 72 hrs by CellTiter-Glo assay Cytotoxicity against human MV411 cells after 72 hrs by CellTiter-Glo assay	[PMID: 30268702]
MV4-11	IC₅₀	0.8 μM Compound: 1; IBET762	Cytotoxicity against human MV4-11 cells assessed as inhibition of cell viability Cytotoxicity against human MV4-11 cells assessed as inhibition of cell viability	[PMID: 30905542]
MV4-11	IC₅₀	112 nM Compound: 1; I-BET762	Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 4 days by CCK8 assay Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition after 4 days by CCK8 assay	[PMID: 31461688]
MV4-11	IC₅₀	1.23 μM Compound: I-BET-762	Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay Antiproliferative activity against human MV4-11 cells assessed as reduction in cell viability incubated for 72 hrs by CCK-8 assay	[PMID: 32631570]
NALM-6	EC₅₀	0.39 μM Compound: 2; GSK525762A	Cytotoxicity against human NALM6 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay Cytotoxicity against human NALM6 cells assessed as reduction in cell viability after 5 days by CellTiter-Glo assay	[PMID: 29170024]
PBMC	IC₅₀	0.2 μM Compound: I-BET762, GSK525762A	Anti-inflammatory activity against LPS-stimulated human PBMC assessed as IL-6 production Anti-inflammatory activity against LPS-stimulated human PBMC assessed as IL-6 production	[PMID: 21964340]
Raji	IC₅₀	0.19 μM Compound: I-BET762	Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs Inhibition of BRD4 in human Raji cells assessed as reduction of MYC expression after 4 hrs	[PMID: 24900758]
THP-1	IC₅₀	0.29 μM Compound: III; I-BET762; GSK-525762A	Antiproliferative activity against human THP1 cells Antiproliferative activity against human THP1 cells	[PMID: 28939121]

In Vitro

Molibresib (I-BET 762) shows the highest affinity interaction with BET. Molibresib binds to the tandem bromodomains of BET with high affinity (dissociation constant K_d of 50.5-61.3 nM). Molibresib displaces, with high efficacy (half-maximum inhibitory concentration IC₅₀ of 32.5-42.5 nM), a tetra-acetylated H4 peptide that had been pre-bound to tandem bromodomains of BET^[1]. Molibresib has high affinity for BD1/BD2 domain of BRD2/3/4 proteins. Molibresib treatment leads to a reduction in the recruitment of all three proteins to chromatin^[2]. Molibresib inhibits OPM-2 cell proliferation with IC₅₀ of 60.15 nM^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

The antimyeloma activity of Molibresib (I-BET 762) is tested dosed orally in an in vivo systemic xenograft model generated by injecting OPM-2 cells into NOD-SCID mice. Daily oral doses of Molibresib up to 10 mg/kg and 30 mg/kg given every other day are well tolerated with no clear impact on body weight compared with vehicle control. The plasma hLC concentration is significantly reduced in mice treated with Molibresib^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 1260907-17-2
Appearance Solid
Molecular Weight 423.90
Formel C₂₂H₂₂ClN₅O₂
Color Off-white to yellow
SMILES

ClC1=CC=C(C2=N[C@@H](CC(NCC)=O)C3=NN=C(C)N3C4=CC=C(OC)C=C24)C=C1
Synonyms

I-BET762; GSK525762; GSK525762A
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (23)

All Flow CytometryBio/Physico-chemical AssayRT-PCRWB

Sort by:

Journal Impact Factor

Nat Med

Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. [Abstract]

2017 Sep;23(9):1055-1062. PMID: 28805822

Molibresib purchased from MedChemExpress. Usage Cited in: Nat Med. 2017 Sep;23(9):1055-1062. [Abstract]

Western blot of WCL of C4-2 cells treated with vehicle (DMSO) or different doses of JQ1 or i-BET for 24 h. Actin is used as a loading control.
Cell

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. [Abstract]

2021 Apr 15;184(8):2167-2182.e22. PMID: 33811809
Cell Metab

Lactate controls cancer stemness and plasticity through epigenetic regulation. [Abstract]

2025 Apr 1;37(4):903-919.e10. PMID: 39933514
Nat Commun

Epigenetic-based differentiation therapy for Acute Myeloid Leukemia. [Abstract]

2024 Jul 2;15(1):5570. PMID: 38956053

Molibresib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]

HL-60 cells were treated daily with 25% GI₅₀ concentrations of CM-444, CM-1758, Molibresib, and JQ1, or CM-444 or CM-1758 in combination with Molibresib or JQ1, for 48 hours. The cell differentiation experiment was performed by detecting CD11b by flow cytometry.

Molibresib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]

ML-2 cells were treated daily with 25% GI₅₀ concentrations of CM-444, CM-1758, Molibresib, and JQ1, or CM-444 or CM-1758 in combination with Molibresib or JQ1, for 48 hours. The cell differentiation experiment was performed by detecting CD11b by flow cytometry.

Molibresib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]

q-PCR results of GATA2, PU.1, SCL and CEBPA in HL-60 cells after daily treatment with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, JQ1, and CM-444 or CM-1758 in combination with Molibresib or JQ1 for 48 hours.

Molibresib purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Jul 2;15(1):5570. [Abstract]

q-PCR results of GATA2, PU.1, SCL and CEBPA in ML-2 cells after daily treatment with 25% GI50 concentrations of CM-444, CM-1758, Molibresib, JQ1, and CM-444 or CM-1758 in combination with Molibresib or JQ1 for 48 hours.
Sci Adv

Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. [Abstract]

2021 Feb 19;7(8):eabe4038. PMID: 33608276

Molibresib purchased from MedChemExpress. Usage Cited in: Sci Adv. 2021 Feb 19;7(8):eabe4038. [Abstract]

Comparison of expression levels of molibresib targets BRD2, BRD3 and BRD4 between leukemic and nonleukemic cells of AML1.
J Exp Med

Convergent roles of ATF3 and CSL in chromatin control of cancer-associated fibroblast activation. [Abstract]

2017 Aug 7;214(8):2349-2368. PMID: 28684431
Cancer Lett

The combination of BET and PARP inhibitors is synergistic in models of cholangiocarcinoma. [Abstract]

2020 Jan 1;468:48-58. PMID: 31605774
Proc Natl Acad Sci U S A

MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. [Abstract]

2019 Feb 19;116(8):2961-2966. PMID: 30718431
Cell Syst

A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]

2018 Apr 25;6(4):424-443.e7. PMID: 29655704
Blood Adv

Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma. [Abstract]

2022 Apr 12;6(7):2346-2360. PMID: 35030628
J Med Chem

Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib. [Abstract]

2020 Jul 9;63(13):7186-7210. PMID: 32453591
Elife

Cohesin mutations are synthetic lethal with stimulation of WNT signaling. [Abstract]

2020 Dec 7;9:e61405. PMID: 33284104
Atherosclerosis

RVX-208, a BET-inhibitor for treating atherosclerotic cardiovascular disease, raises ApoA-I/HDL and represses pathways that contribute to cardiovascular disease. [Abstract]

2016 Apr:247:48-57. PMID: 26868508
Commun Biol

Three-dimensional CRISPR screening reveals epigenetic interaction with anti-angiogenic therapy. [Abstract]

2021 Jul 15;4(1):878. PMID: 34267311
Harvard University

2026.
bioRxiv

2026 May 7.
bioRxiv

2026 Jan 9.
bioRxiv

BRD2 Upregulation as a Pan-Cancer Adaptive Resistance Mechanism to BET Inhibition. [Abstract]

2025 Sep 3:2025.08.30.673282. PMID: 40949948
bioRxiv

AI-assisted Drug Re-purposing for Human Liver Fibrosis. [Abstract]

2025 May 4:2025.04.29.651320. PMID: 40654780
SSRN

2024 Apr 6.
Patent

US20220016130A1.
Patent

US20180263995A1.
Oncotarget

BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. [Abstract]

2016 Jun 21;7(25):38319-38332. PMID: 27223260

Molibresib purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 Jun 21;7(25):38319-38332. [Abstract]

iBET762 partially disrupts the interaction between full-length ERG and BRD4 (A), and between T1-E4 ERG and BRD4 (B).

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 200 mg/mL (471.81 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

1M HCl : 100 mg/mL (235.90 mM; ultrasonic and adjust pH to 1 with HCl)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.3590 mL

11.7952 mL

23.5905 mL

5 mM

0.4718 mL

2.3590 mL

4.7181 mL

10 mM

0.2359 mL

1.1795 mL

2.3590 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

Protocol 3

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.90 mM); Clear solution

Protocol 4

Add each solvent one by one: 1% DMSO 99% Saline

Solubility: ≥ 0.5 mg/mL (1.18 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

VCaP, LNCaP, 22RV1, DU145 and PC3 prostate cancer cell lines are seeded in 96-well plates at 2000-10,000 cells/well (optimum density for growth) in a total volume of 100μL media containing 10% FBS. Serially diluted compounds in 100μL media are added to the cells 12hr later. Following 96 hr. incubation, cell viability is assessed by Cell-Titer GLO. The values are normalized and IC₅₀ is calculated using GraphPad Prism software. For long-term colony formation assay, 10,000-50,000 cells/well are seeded in six-well plates and treated with either 100 nM or 500 nM of JQ1 or DMSO. After 12 days cells are fixed with methanol, stained with crystal violet and photographed. For colorimetric assays, the stained wells are treated with 500μL 10% acetic acid and the absorbance is measured at 560nm using a spectrophotometer^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]

Mice^[3]
The antimyeloma efficacy of orally administered Molibresib is tested in a systemic xenograft myeloma model. For this purpose, sublethally irradiated (200 cGy) NOD/SCID mice age 9 to 11 weeks are given 10⁷ OPM-2 myeloma cells via tail vein injection. On day 15 following inoculation, animals are started on oral treatment with Molibresib at escalating doses or vehicle (1% methylcellulose and 0.2% sodium lauryl sulfate), which is continued up to day 83. Specifically, 1 group of mice are treated with vehicle and 4 groups with different dosing schedules of Molibresib: 3 mg/kg per day; 10 mg/kg per day; 30 mg/kg on alternate days; and 30 to 20 mg/kg per day (ie, 30 mg/kg per day for 14 days, followed by 2 weeks [days 15 to 31] off treatment [drug is withheld due to a decline in body weight until animals has regained weight], follow by 20 mg/kg per day until termination of the experiment [days 43 to 82]). Blood samples (~70 μL) are removed at 0.5 hours after oral administration of Molibresib on day 15 (treatment initiation); days 27, 45, and 82 (3, 10, and 20 to 30 mg/kg once per day groups only); and day 83 (30 mg/kg once every other day group only). The blood is centrifuged to obtain 20 μL plasma and stored at -20°C prior to analysis for Molibresib by using a specific liquid chromatography/mass spectrometry/mass spectrometry assay.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nicodeme E, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010 Dec 23;468(7327):1119-23. [Content Brief]

[2]. Asangani IA, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014 Jun 12;510(7504):278-82. [Content Brief]

[3]. Chaidos A, et al. Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood. 2014 Jan 30;123(5):697-705. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
1M HCl / DMSO	1 mM	2.3590 mL	11.7952 mL	23.5905 mL	58.9762 mL
	5 mM	0.4718 mL	2.3590 mL	4.7181 mL	11.7952 mL
	10 mM	0.2359 mL	1.1795 mL	2.3590 mL	5.8976 mL
	15 mM	0.1573 mL	0.7863 mL	1.5727 mL	3.9317 mL
	20 mM	0.1180 mL	0.5898 mL	1.1795 mL	2.9488 mL
	25 mM	0.0944 mL	0.4718 mL	0.9436 mL	2.3590 mL
	30 mM	0.0786 mL	0.3932 mL	0.7863 mL	1.9659 mL
	40 mM	0.0590 mL	0.2949 mL	0.5898 mL	1.4744 mL
	50 mM	0.0472 mL	0.2359 mL	0.4718 mL	1.1795 mL
	60 mM	0.0393 mL	0.1966 mL	0.3932 mL	0.9829 mL
	80 mM	0.0295 mL	0.1474 mL	0.2949 mL	0.7372 mL
	100 mM	0.0236 mL	0.1180 mL	0.2359 mL	0.5898 mL

Keywords

Molibresib

23 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Molibresib

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Molibresib

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Molibresib

Epigenetics Compound Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Reprogramming Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Protein-protein Interaction Inhibitor Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

High-Throughput Bioactive Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Molibresib

Alle Epigenetic Reader Domain Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (23)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Molibresib Related Classifications

Art. -Nr.: HY-13032